TB-500 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

TB-500

Also known as: Thymosin beta-4 fragment, Ac-LKKTETQ, N-acetyl-LKKTETQ, Tβ4 fragment (17-23), Thymosin beta-500

Synthetic peptide fragment (actin-binding / tissue repair peptide); derived from the active site of thymosin beta-4 (Tβ4)

Not FDA-approvedLast updated: October 31, 2026Based on 14 peer-reviewed studies

What it is

TB-500 is a peptide people use to speed recovery from tendon, muscle, and wound injuries, and to support athletic performance. It works by activating pathways that promote the formation of new blood vessels and tissue repair. Not FDA-approved; banned by WADA; sold as a gray-market research compound.

The scientific side

TB-500 is the synthetic N-terminal acetylated heptapeptide fragment (Ac-LKKTETQ) corresponding to residues 17–23 of thymosin beta-4 (Tβ4), representing the actin-binding active site of the parent protein. In its unacetylated form (LKKTETQ), biological functions include actin binding, dermal wound healing, angiogenesis, and skin repair. TB-500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition, and decreased inflammation. Reviews describe TB-500 as promoting angiogenesis and tissue repair in preclinical models, and acting via integrin-mediated extracellular matrix remodeling and fibroblast activation (PMID 41490200; PMID 41476424). Metabolic studies found that the primary metabolites are Ac-LK (highest concentration at 0–6 h) and Ac-LKK (detectable up to 72 h), and suggest that previously reported wound-healing activity may be attributable to the metabolite Ac-LKKTE rather than the parent compound itself.

Class: Synthetic peptide fragment (actin-binding / tissue repair peptide); derived from the active site of thymosin beta-4 (Tβ4)

Not FDA-approvedLow researchHormonesBonesSynthetic thymosin beta-4 fragment

At a glance

What it isA synthetic 7-amino-acid peptide, Ac-LKKTETQ: residues 17-23 of the natural protein thymosin beta-4, with an acetyl group added.
FDA statusNot approved for any use. An FDA advisory committee voted 8-6 in July 2026 to let compounding pharmacies make it; that vote is a recommendation only.
Used forMuscle, tendon and wound recovery, based on animal and cell studies of thymosin beta-4.
Human evidenceNone for TB-500 itself. Human trials exist only for full-length thymosin beta-4, a different, larger molecule.
Half-lifeNot measured. In rats, a breakdown product stayed detectable in urine for up to 72 hours.
Banned in sportYes. WADA names it under S2.3 (growth factors), prohibited at all times.

What is TB-500?

TB-500 is a synthetic peptide with the sequence Ac-LKKTETQ. It copies a short stretch, residues 17 to 23, of thymosin beta-4, a 43-amino-acid protein found in almost every cell. Equine doping chemists describe it as "a synthetic version of an active region of thymosin beta4".

The name causes confusion: TB-500 is often sold as if it were thymosin beta-4, and some vendors describe it as 17 amino acids, a mix-up with the residue numbers. Studies of full-length thymosin beta-4 do not tell you what the 7-amino-acid fragment does in people. It is commonly stacked with BPC-157.

Sources: [1] [2]

How does it work?

The LKKTETQ stretch is the part of thymosin beta-4 that binds actin, a protein cells use to move and change shape. In cell and animal studies this region promoted cell migration, new blood vessel growth and wound healing.

Whether the short fragment reproduces the effects of the full protein in people is unknown. A 2024 rat study found TB-500 is quickly cut into smaller pieces; the authors suggested one of them may carry the wound-healing activity.

Pharmacokinetics

Half-lifeNot measured for TB-500 (no human or animal half-life published)
MetabolismRapidly cut into smaller fragments; Ac-LK was the main metabolite in rats (animal data)
ClearanceBreakdown product Ac-LKK detectable in rat urine for up to 72 hours (animal data)
RouteNo human data for TB-500; sold for injection under the skin or into muscle

Sources: [3] [4]

Is it FDA-approved?

No. TB-500 has never been approved for any use, and no company has tested it in a human trial.

FDA placed it on its list of compounding substances with significant safety risks ("Category 2") in September 2023. FDA wrote that it "has not identified any human exposure data" for it and flagged immunogenicity and impurity risks. By April 2026 FDA listed it as nominated but withdrawn. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted 8-6, with 1 abstention, to recommend it for the list of substances compounding pharmacies may use. That vote is not binding; FDA would still need to complete rulemaking.

  • WADA: S2.3 Growth factors and growth factor modulators ("Thymosin-ß4 and its derivatives e.g. TB-500"; prohibited at all times)

Sources: [2] [5] [6]

History

Thymosin beta-4 is a natural protein that binds actin inside cells. Research groups mapped which short stretches of it carry its effects; a 2010 study tied the 17-23 region to cell migration, blood vessel growth and wound healing.

The full protein went into clinical development, including eye drops and an IV form. TB-500, the short synthetic fragment, took a different path: it appeared in horse racing, where a 2012 paper described a doping test for it, and then in the human grey market for recovery.

Sources: [3] [7] [8] [1]

Regulatory timeline

  1. September 29, 2023FDA places "thymosin beta-4, fragment (LKKTETQ)" in Category 2 (503A), citing immunogenicity and impurity risks and no human exposure data. Source
  2. April 2026FDA lists it under "nominated but withdrawn", so it is no longer in Category 2. FDA's page was updated April 22, 2026. Source
  3. July 23, 2026FDA's Pharmacy Compounding Advisory Committee votes 8-6, with 1 abstention, to recommend TB-500 for the 503A bulks list. The vote is a non-binding recommendation. Source
  4. As of October 2026Still not FDA-approved. Compounding would still require FDA to accept the recommendation and complete rulemaking. Source

Side effects

There are no human side-effect data for TB-500. Trials of full-length thymosin beta-4 given by IV to healthy volunteers reported no dose-limiting toxicities or serious adverse events, but that is a different molecule, given by a different route.

Two concerns come up repeatedly. FDA flagged a risk of immune reactions from aggregation and impurities. And in a 2003 mouse study, cancer cells engineered to overproduce thymosin beta-4 formed larger tumors and more metastases with more blood vessels; whether injected TB-500 has any similar effect is unknown.

Who should not use it

  • No established contraindications: TB-500 has never been through human trials.
  • Competitive athletes: prohibited at all times under WADA S2.3.
  • Active or past cancer: animal data link thymosin beta-4 to tumor blood vessel growth, so caution is reasonable.
  • Pregnancy and breastfeeding: not studied.

No human trial of TB-500 has been published. Safety data cited online come from trials of full-length thymosin beta-4.

Sources: [8] [9] [2] [10]

What does the research show?

No clinical trial of TB-500 has been published. The human trials people cite used full-length thymosin beta-4. Two phase 1 studies of IV thymosin beta-4 in healthy volunteers (40 and 84 people) found it well tolerated. A small phase 3 trial of thymosin beta-4 eye drops for a corneal healing disorder found complete healing in 6 of 10 treated patients versus 1 of 8 on placebo, a result that just missed statistical significance (p = 0.0656).

For TB-500 itself, the published work is analytical and animal-based: methods to detect it in horses, and a rat study tracking how it breaks down.

Studied for

  • Wound healing and cell migration (cell and animal studies)
  • Doping detection in horses (analytical studies)
  • Full-length thymosin beta-4, not TB-500: corneal healing, skin wounds, heart injury (human trials)

Sources: [8] [9] [7] [1] [4]

FAQ

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-amino-acid protein. TB-500 is a 7-amino-acid synthetic copy of one region of it (residues 17-23).

Sources: [1]

Has TB-500 been tested in humans?

No. The human trials people cite tested full-length thymosin beta-4, a different and much larger molecule. FDA says it has not identified any human exposure data for TB-500.

Sources: [2] [8]

Is TB-500 FDA-approved?

No, not for any use. The July 2026 advisory committee vote was about compounding, not approval, and it was a recommendation only.

Sources: [5]

Can a compounding pharmacy make TB-500 now?

Not under the normal 503A route yet. FDA would have to accept the July 2026 recommendation and finish proposed and final rulemaking before adding it to the bulks list.

Sources: [5] [6]

Is TB-500 banned in sport?

Yes. The 2026 WADA Prohibited List names "Thymosin-ß4 and its derivatives e.g. TB-500" under S2.3, prohibited at all times.

Sources: [11]

Can TB-500 cause cancer?

There is no evidence it does. The concern comes from a 2003 mouse study where cancer cells overproducing thymosin beta-4 formed larger, more vascular tumors. Nobody has tested whether injected TB-500 does anything similar.

Sources: [10]

How long does TB-500 stay in the body?

Its half-life has not been measured. In rats it was quickly broken down, and one fragment stayed detectable in urine for up to 72 hours.

Sources: [4]

Citations

  1. Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma. J Chromatogr A 2012. PMID 23084823
  2. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  3. Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J 2010. PMID 20179146
  4. Rahaman KA, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats. J Chromatogr B 2024. PMID 38382158
  5. Steinzor P. FDA panel backs 6 peptides for compounding. AJMC, July 31, 2026. ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
  6. FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee. fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
  7. Sosne G, et al. 0.1% RGN-259 (thymosin beta4) ophthalmic solution in neurotrophic keratopathy: a randomized phase III trial. Int J Mol Sci 2022. PMID 36613994
  8. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci 2010. PMID 20536472
  9. Wang X, et al. A first-in-human phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med 2021. PMID 34346165
  10. Cha HJ, et al. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst 2003. PMID 14625258
  11. World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf

Sources

Modified Forms

The following chemical variants are structurally derived from this peptide. They are documented here rather than on separate pages.

TB-500 Fragment (17-23) — LKKTETQ

TB-500 Fragment (17-23), sequence LKKTETQ, is the seven-amino-acid actin-binding domain extracted from full TB-500 (Thymosin Beta-4, 43 amino acids). The fragment retains G-actin sequestering activity, which drives cell migration underlying wound healing and angiogenesis, but lacks the remaining 36 amino acids of the parent protein. Molecular weight is approximately 829 Da versus 4963 Da for full TB-500. Animal studies confirm wound healing activity comparable to the full peptide in dermal wound models (PMID: 12581423, 17001601). The fragment is detected in equine anti-doping samples at 10 mg doses (PMID: 23084823). All evidence is preclinical. The form is typically supplied as N-acetylated LKKTETQ (Ac-LKKTETQ).

How dosing differs: A single 10 mg dose was detected in equine anti-doping research (PMID: 23084823). No human dose-finding studies exist. Community dosing typically mirrors full TB-500 protocols (500 mcg–2 mg subcutaneous), though fragment-specific human data is absent. The smaller molecular weight may affect pharmacokinetics relative to the full peptide.

Key differences from parent: Smaller molecule (~829 Da vs ~4963 Da) with potentially improved tissue penetration and lower synthesis cost. Retains the actin-sequestering LKKTETQ core but lacks the full parent sequence's additional structural and signalling elements. Fragment-specific PMIDs confirm independent wound healing activity in rodent and ophthalmic models.

Form-specific studies: PMID 12581423 PMID 17001601 PMID 23084823 PMID 38382158 PMID 41359360

Administration & storage

Administration
Intraperitoneal injection — used in rat Achilles tendon study (PMID: 42542926)Subcutaneous injection — reported in equine administration study (PMID: 23318763)
Storage
One anti-doping study noted that −20°C was found to be the appropriate storage temperature for peptides including TB-500 in urine for sports drug testing purposes. No other storage conditions for TB-500 preparations are described in the reviewed abstracts.
Cautions
TB-500 has no established human safety profile; reviewed literature describes it as an unapproved compound with scarce rigorous human safety data and potential for serious patient harm.,Unregulated injectable peptides, including TB-500, carry risks of product contamination, manufacturing impurities, inaccurate dosing, pathological angiogenesis, and carcinogenesis.,Compounded or gray-market peptide preparations may not meet pharmaceutical manufacturing standards, increasing risk of impurities (PMID: 42757290; PMID: 41966639).,TB-500 is a WADA-prohibited substance; use by competitive athletes may result in anti-doping rule violations (PMID: 41476424; PMID: 26578461).,Sterile technique is essential for any injectable preparation to reduce infection risk.

Legal & regulatory status

US FDA

Not approved for human use by the FDA. Reviewed literature describes TB-500 as an unapproved, investigational compound operating in a 'gray market'. One review notes most of these therapies remain unapproved by the U.S.…

WADA

Listed as a prohibited substance on the WADA Prohibited List. Multiple anti-doping publications describe TB-500 as a WADA-prohibited substance and doping-relevant compound (PMID: 26578461; PMID: 41476424). Reviewed…

Health Canada

Not stated in reviewed literature — requires manual verification